Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 6/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 3/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6974985 | 0.91 | F2 (0.41) | F2F10MAPK14 | |
| SCHEMBL6979249 | 0.89 | F2 (0.41) | F2F10MAPK14PARP1 | |
| SCHEMBL6983681 | 0.88 | F2 (0.42) | F2F10MAPK14 | |
| SCHEMBL6979762 | 0.88 | F2 (0.41) | F2F10MAPK14MEN1KMT2A | |
| SCHEMBL6978159 | 0.87 | F10 (0.42) | F2F10MAPK14 | |
| SCHEMBL6982478 | 0.87 | ROCK1 (0.42) | F2F10MAPK14 | |
| SCHEMBL6983741 | 0.87 | F2 (0.38) | F2F10MAPK14MEN1KMT2A | |
| SCHEMBL6984824 | 0.85 | F10 (0.50) | F2F10 | |
| SCHEMBL6979831 | 0.85 | F10 (0.44) | F2F10KMT2A | |
| SCHEMBL6979694 | 0.84 | F10 (0.42) | F2F10MEN1KMT2APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1012166-B1 | 1-AMINO-7-ISOQUINOLINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2003-10-29 | — | — | EP | disclosed |
| US-6420438-B1 | FOR THERAPY OF THROMBOTIC DISEASE, ASTHMA, EMPHYSEMA, CIRRHOSIS, ARTHRITIS, CARCINOMA, MELANOMA, RESTENOIS, ATHEROMA, TRAUMA, SHOCK AND REPERFUSION INJURY | TULARIK LIMITED (GB) | 2002-07-16 | — | — | US | disclosed |
| US-20020040144-A1 | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2002-04-04 | — | — | US | disclosed |
| US-6262069-B1 | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040144-A1 | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | CTRL, HPN, CTSL | F2 776/4885F10 1211/4885MAPK14 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.